Integrated Analysis of Microbiome and Serum Metabolomics to Understand How Rauvolfia vomitoria Alkaloids Inhibit Colorectal Cancer Growth
4 affiliations
- 1Department of Pharmacy, , Jinan 250012, China;
- 2School of Pharmaceutical Science, , 44# West Wenhua Road, Jinan 250012, China;
- 3Shandong Institute for Food and Drug Control, Jinan 250101, China;
- 4Department of Pain Management, , Jinan 250012, China
Abstract
Background/Objectives: Rauvolfia vomitoria alkaloids (RVA) exhibited excellent activity against colorectal cancer (CRC) growth in the heterotopic model. However, their antitumor effects in the orthotopic models, as well as the underlying mechanisms related to gut microbiota and serum metabolomics, remain poorly understood. Methods: We performed 16S rRNA sequencing and serum metabolomics analysis in orthotopic CRC-bearing mice following different treatments. Univariate and multivariate logistic regression analyses were used to screen key gut microbes and metabolites associated with RVA treatments. KEGG enrichment analysis was conducted to identify the metabolic pathways modulated by RVAs in vivo. Results: RVA, either alone or in combination with 5-Fluorouracil (5-FU), exhibited a potent inhibitory effect on CRC growth, comparable to intraperitoneally administered 5-FU. In terms of body weight and organ indices, RVA showed lower toxicity compared to 5-FU. Both treatments induced measurable shifts in the gut microbial profiles of CRC mice. Increased abundance of Akkermansia and Lactobacillus and decreased abundance of Enterococcus were found to be associated with RVA monotherapy. The enrichment of Acinetobacter and Mucispirillum in CRC mice was suppressed by the combination treatment. A serum metabolomics study revealed that linoleic acid metabolism and β-oxidation of long-chain fatty acids were modulated by both RVA-containing regimens. Conclusions: These findings demonstrate that oral administration of RVA, either alone or combined with current clinical therapeutic methods, may represent a promising strategy for CRC treatment. Targeted modulation of gut microbiota and fatty acid metabolism may provide promising approaches to hinder CRC progression.
Related
- Untargeted metabolomics in microbiome-immune crosstalk in cancer: challenges and recommendations for functional interpretation
- Integrated Spatial Metabolomics and Proteomics from the Same Tissue Section Using a Conductive ITO-PET Slide
- Gut microbiome features associated with PIK3CA-mutated colorectal cancer: A nationwide pan-cancer genomic and microbial profiling study (MONSTAR-SCREEN)
- Integrated non-targeted metabolomics, volatile profiling and targeted quantification characterize chemical changes in Jinhua jasmine tea during the scenting process
- Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods
BibTeX
@article{zhang2026integrated,
title = {{Integrated Analysis of Microbiome and Serum Metabolomics to Understand How Rauvolfia vomitoria Alkaloids Inhibit Colorectal Cancer Growth}},
author = {Yanli Zhang and Zhifan Wang and Weiliang Cui and Jianfeng Wang and Shuqi Wang},
journal = {Pharmaceutics},
year = {2026},
month = oct,
doi = {10.3390/pharmaceutics18101272},
url = {https://europepmc.org/article/PMC/PMC13708475},
note = {CC BY},
}
RIS
TY - JOUR
TI - Integrated Analysis of Microbiome and Serum Metabolomics to Understand How Rauvolfia vomitoria Alkaloids Inhibit Colorectal Cancer Growth
AU - Yanli Zhang
AU - Zhifan Wang
AU - Weiliang Cui
AU - Jianfeng Wang
AU - Shuqi Wang
PY - 2026
DA - 2026/10/01
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101272
UR - https://europepmc.org/article/PMC/PMC13708475
AB - Background/Objectives: Rauvolfia vomitoria alkaloids (RVA) exhibited excellent activity against colorectal cancer (CRC) growth in the heterotopic model. However, their antitumor effects in the orthotopic models, as well as the underlying mechanisms related to gut microbiota and serum metabolomics, remain poorly understood. Methods: We performed 16S rRNA sequencing and serum metabolomics analysis in orthotopic CRC-bearing mice following different treatments. Univariate and multivariate logistic regression analyses were used to screen key gut microbes and metabolites associated with RVA treatments. KEGG enrichment analysis was conducted to identify the metabolic pathways modulated by RVAs in vivo. Results: RVA, either alone or in combination with 5-Fluorouracil (5-FU), exhibited a potent inhibitory effect on CRC growth, comparable to intraperitoneally administered 5-FU. In terms of body weight and organ indices, RVA showed lower toxicity compared to 5-FU. Both treatments induced measurable shifts in the gut microbial profiles of CRC mice. Increased abundance of Akkermansia and Lactobacillus and decreased abundance of Enterococcus were found to be associated with RVA monotherapy. The enrichment of Acinetobacter and Mucispirillum in CRC mice was suppressed by the combination treatment. A serum metabolomics study revealed that linoleic acid metabolism and β-oxidation of long-chain fatty acids were modulated by both RVA-containing regimens. Conclusions: These findings demonstrate that oral administration of RVA, either alone or combined with current clinical therapeutic methods, may represent a promising strategy for CRC treatment. Targeted modulation of gut microbiota and fatty acid metabolism may provide promising approaches to hinder CRC progression.
SN - 1999-4923
ER -